Interim results for the 6 months ended 30 June 26

Oxford Nanopore posts improved margins and lower losses, but China sales fall sharply.

What the company is saying

Oxford Nanopore frames its interim results as evidence of strong operational progress, highlighting a 12.3% constant-currency revenue increase to £116.7 million and a 400 basis point gross margin improvement to 62.2%. The company emphasizes that its adjusted EBITDA loss more than halved to £22.1 million, and the period loss narrowed to £48.0 million, presenting these as signs of improving efficiency and financial discipline. Cash reserves of £234.5 million are presented as a foundation for continued investment and stability. Management spotlights a new global cross-licensing agreement, specifying a $20 million licensing fee for H2 FY26 and $15 million in future product purchases, to underscore near-term revenue visibility. Forward-looking statements include ambitions for adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28, but these are presented as targets rather than binding forecasts. The company briefly acknowledges a 15.7% revenue decline in China but does not dwell on regional challenges. The overall tone is confident and forward-leaning, with selective quantification of realised results and aspirational language around future growth.

What the data suggests

The reported numbers confirm a positive financial trajectory for H1 2026: revenue grew by 12.3% on a constant currency basis and 10.5% on a reported basis, reaching £116.7 million. Gross margin rose to 62.2%, up 400 basis points, indicating improved cost control or product mix. Adjusted EBITDA loss fell to £22.1 million, more than halving year-on-year, and the period loss narrowed to £48.0 million, both pointing to operational leverage. Cash and liquid investments stood at £234.5 million at period end, providing a strong liquidity buffer. Regional data reveals a 15.7% sales decline in China, which offsets some of the global growth and signals market-specific headwinds. The $20 million licensing fee is contractually committed for H2 FY26, providing near-term revenue certainty, while the $15 million in product purchases will be recognized over FY27 and FY28, extending the revenue tail. No quantified financial impact is disclosed for the MyOme agreement or for anticipated royalty streams, and forward-looking targets for EBITDA breakeven and free cash flow lack supporting detail. The data is robust for realised results but thin for projections and new initiatives.

Analysis

The announcement presents a positive tone, supported by measurable improvements in revenue, gross margin, and a reduced EBITDA loss. These realised results are clearly disclosed and substantiated by numerical data. However, several forward-looking claims—such as targeted EBITDA breakeven in FY27, positive free cash flow in FY28, and anticipated royalties—are not accompanied by detailed projections or binding commitments, limiting their evidentiary value. The $20 million licensing fee is a near-term, contractually committed milestone, but the additional $15 million in product purchases and future royalty streams are longer-dated and less certain. There is no indication of a large new capital outlay in this period, and the company’s cash position is strong. The gap between narrative and evidence is moderate: while operational progress is real, some language inflates future potential without full quantification.

Risk flags

• ●The 15.7% revenue decline in China signals significant regional risk, as it contrasts with overall group growth and may indicate competitive, regulatory, or macroeconomic headwinds in a key market.
• ●Forward-looking targets for adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28 are not supported by detailed financial bridges or interim milestones, raising execution risk if operational improvements stall.
• ●Projected royalty income is described only in qualitative terms ('low-to-mid-single-digit percentage'), with no quantification or minimum guarantees, making the future revenue contribution from this stream highly uncertain.
• ●The $15 million in committed product purchases from the cross-licensing agreement is scheduled for recognition over FY27 and FY28, but no information is provided on the counterparty's creditworthiness or the enforceability of the commitment, introducing counterparty risk.
• ●No financial impact or revenue projections are disclosed for the MyOme agreement, so its contribution to future growth remains speculative and unquantified.

Bottom line

Oxford Nanopore's interim results show clear operational progress, with revenue up 12.3% (constant currency), gross margin reaching 62.2%, and losses narrowing on both an EBITDA and net basis. The company's cash position of £234.5 million supports ongoing investment and reduces short-term financial risk. Near-term revenue visibility is strengthened by a $20 million licensing fee to be recognized in H2 FY26, but the $15 million in future product purchases and any royalty income are longer-dated and less certain. The 15.7% sales decline in China is a material negative, highlighting regional volatility that could persist. Forward-looking targets for EBITDA breakeven and free cash flow are aspirational, lacking granular detail or binding commitments. The MyOme agreement and anticipated royalties are not yet supported by numbers, so their investment impact is unclear. For investors, the main takeaway is that realised financial improvements are genuine, but the pathway to sustained profitability and growth depends on execution and delivery of currently unquantified forward-looking initiatives.

Announcement summary

(LSE: ONT) Oxford Nanopore Technologies plc announced its interim results for the six months ended 30 June 2026, reporting group revenue of £116.7 million, which grew by 12.3% on a constant currency basis and 10.5% on a reported basis. Gross margin increased by 400 basis points to 62.2%, and the adjusted EBITDA loss more than halved year-on-year to £22.1 million. Loss for the period reduced year-on-year to £48.0 million. The company reported cash, cash equivalents and other liquid investments of £234.5 million as at 30 June 2026. Regional performance included a 15.7% decline in China. The Group entered into a new global cross-licensing agreement with a $20 million licensing fee to be recognised in H2 FY26 and an additional $15 million in committed product purchases to be recognised over FY27 and FY28.

Disagree with this article?